Cytori Therapeutics Says ATHENA Study Supports Symptomatic Benefit From Its Cell Therapy

By: via Benzinga
Cytori Therapeutics Inc (NASDAQ: CYTX) revealed the presentation of six, as well as, the 12-month data from the ATHENA studies at the ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.